Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT02279433 trial: what clinicians have said so far
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
- NCT02279433 ↗
- Completed
- Nuvation Bio Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02279433 (taletrectinib in metastatic and/or unresectable solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02279433 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Solid Tumors
- Interventions
- DS6051b
- Arms
- DS-6051b · Experimental
- Enrollment
- 46
- Primary outcomes
- Part 1: Number of participants with dose-limiting toxicities
- Tumor response
- Sponsor
- Nuvation Bio Inc. with AnHeart Therapeutics Inc.
- Start
- Sep 2014
- Primary completion
- Mar 2019
- Results posted
- No
- Registry record
- NCT02279433 · updated Jun 24, 2025